Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near-Future Clinical Integration

Download All
Learn how experts apply practice-changing clinical data to integrate the use of BCMA-targeted agents for their patients with multiple myeloma, with focused commentaries, a healthcare professional resource, and a module with downloadable slides.
Sagar Lonial, MD
Nina Shah, MD


Read this module from Nina Shah, MD, to learn more about how BCMA-targeted agents work in multiple myeloma and how you can use these agents in clinical practice to improve patient outcomes.

Nina Shah, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 4, 2022 Expired: April 3, 2023

Downloadable Slideset

Download these slides with the most recent data on BCMA-targeted agents in multiple myeloma, including information on mechanism of action, clinical trial data, and implications for clinical practice.

Released: April 4, 2022


Learn how experts incorporate BCMA-directed therapies for multiple myeloma into their practice.

Nina Shah, MD Released: February 2, 2022

We’ve heard a great deal about BCMA-targeted CAR T-cell therapy and antibody–drug conjugates for R/R MM. In this commentary, Dr Sagar Lonial discusses how BCMA-targeted bispecific therapies will fit in to the treatment landscape.

Sagar Lonial, MD Released: April 14, 2022

Downloadable Resource

Download this resource developed to serve as a helpful guide for healthcare professionals on the use of BCMA-targeted therapies for treatment of multiple myeloma.

Released: May 2, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings